Abstract 50P
Background
Emerging data suggest that an immune checkpoint inhibitor in combination with chemotherapy is a reasonable strategy for advanced biliary tract cancer (aBTC). Apatinib, an oral TKI selectively targeting VEGFR2 has been shown to reshape the immune microenvironment and enhance the efficacy of camrelizumab (an anti-PD-1 antibody) in several cancers. We therefore designed this study to explore the efficacy and safety of apatinib plus Cam and GP in aBTC and especially the optimal dose of apatinib in this strategy.
Methods
This prospective, 2-part, dose escalation and expansion study enrolled patients (pts) with aBTC. Pts would receive Cam (200mg) and GP (gemcitabine 1000mg/m2 and cisplatin 25mg/m2, iv, d1 and d8; up to 6 cycles) plus apatinib in 21-day cycles. In the phase Ib, a 3+3 dose-escalation design is used to determine the recommended phase 2 dose (RP2D) of apatinib (250 mg, qd; A: d1-d7, B: d1-d10, C: d1-d14). Phase II-dose expansion part is to evaluate the primary endpoint of objective response rate (ORR).
Results
As of April 2024, 17 pts had been treated with a median age of 56 years (range 40-71) and 12 were females. Of 9 pts in phase Ib, 7 had stable disease (SD) and 2 had partial response (PR). No DLTs were reported, and PR was only observed in cohort C. Therefore, the RP2D of apatinib in combination with Cam + GP was defined as 250 mg, d1-d14 and 8 pts were enrolled in phase II. 3 pts (37.5%) achieved PR in this phase. With a median follow-up of 3 months (range, 1-5), 6 pts remained response. Best response and the most common TEAEs are summarized in the following table. Table: 50P
Cohort | A | B | C | Total |
Dose frequency of apatinib (q3w) | d1-d7 | d1-d10 | d1-d14 | |
N | 3 | 3 | 3 + 8 | 17 |
Responses | ||||
Objective response rate (CR + PR), n/N (%) | 1/3(33) | 2/3(67) | 5/11(45) | 8/17(47) |
Disease control (CR + PR + SD), n/N (%) | 3/3(100) | 3/3(100) | 11/11(100) | 17/17(100) |
TEAEs, n (%) | ||||
Alanine aminotransferase increased | 2(67) | 3(100) | 11(100) | 16(94) |
Aspartate aminotransferase increased | 2(67) | 3(100) | 11(100) | 16(94) |
Platelet count decreased | 3(100) | 3(100) | 10(91) | 16(94) |
White blood cell decreased | 2(67) | 3(100) | 9(82) | 14(82) |
Neutrophil count decreased | 1(33) | 3(100) | 9(82) | 14(82) |
Nausea | 2(67) | 1(33) | 7(64) | 11(65) |
Malaise | 2(67) | 2(67) | 7(64) | 11(65) |
Alopecia | 2(67) | 2(67) | 7(64) | 11(65) |
Grade ≥3 | 3(100) | 3(100) | 8(73) | 14(82) |
Conclusions
The efficacy signal support apatinib 250 mg, d1-d14 as an optimal dose when in combination with GP and Cam in aBTC. This combination strategy showed modest efficacy and tolerable adverse events in aBTC. The trial is still recruiting and more data would be further analyzed and reported.
Clinical trial identification
NCT05742750.
Editorial acknowledgement
Guiqin Su, Xiaoqiang Fang (Jiangsu Hengrui Pharmaceuticals Co., Ltd.) provided editorial assistance.
Legal entity responsible for the study
The authors.
Funding
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2008P - Assessing response durability and survival after second-line pembrolizumab in advanced urothelial carcinoma: A multicenter validation of a risk model
Presenter: Samer Salah
Session: Poster session 13
2010P - Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study
Presenter: Aleksander Antoniewicz
Session: Poster session 13
2011P - Neoadjuvant immunotherapy-driven bladder preservation for muscle-invasive bladder cancer: A multicenter, propensity score-matched cohort study
Presenter: Jiao Hu
Session: Poster session 13
2012P - Role of first-line immunotherapy in urothelial cancer with bone metastases: A national cancer database analysis of 3971 patients
Presenter: Zin Myint
Session: Poster session 13
2013P - First preliminary results of artificial intelligence generated treatment recommendations for urothelial cancer based on multidisciplinary cancer conferences from the KITTU project
Presenter: Gregor Duwe
Session: Poster session 13
2014P - Overall survival (OS) results in phase II trial of cabozantinib (CABO) plus durvalumab (DURVA) in patients with urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy (ARCADIA)
Presenter: Patrizia Giannatempo
Session: Poster session 13
2015P - Serum nectin-4: Prognostic and predictive value in bladder cancer?
Presenter: Kerstin Junker
Session: Poster session 13
2016P - Evaluation of event-free survival (EFS) as a surrogate endpoint for overall survival (OS) in muscle-invasive bladder cancer (MIBC) following neoadjuvant (NAD) therapy
Presenter: Cora Sternberg
Session: Poster session 13
2017P - Intrinsic molecular difference between bladder and upper tract urothelial carcinomas and its impacts in treatment response
Presenter: Jiwon Kim
Session: Poster session 13